The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
出版年份 2012 全文链接
标题
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
作者
关键词
-
出版物
Blood Cancer Journal
Volume 2, Issue 5, Pages e69-e69
出版商
Springer Nature
发表日期
2012-05-04
DOI
10.1038/bcj.2012.14
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
- (2011) A R A Razak et al. BRITISH JOURNAL OF CANCER
- FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
- (2011) F Bertolini et al. BRITISH JOURNAL OF CANCER
- Bone Marrow Stroma-Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor
- (2011) T. Manshouri et al. CANCER RESEARCH
- c-Cbl and Cbl-b Ligases Mediate 17-Allylaminodemethoxygeldanamycin-induced Degradation of Autophosphorylated Flt3 Kinase with Internal Tandem Duplication through the Ubiquitin Proteasome Pathway
- (2011) Gaku Oshikawa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
- (2011) K C Goh et al. LEUKEMIA
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
- (2011) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells
- (2011) Hua Xiong et al. MOLECULAR CARCINOGENESIS
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
- (2010) Thomas Prebet et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Deactylase inhibition in myeloproliferative neoplasms
- (2010) Sridurga Mithraprabhu et al. INVESTIGATIONAL NEW DRUGS
- Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation
- (2010) M Buchwald et al. LEUKEMIA
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
- (2010) A Quintás-Cardama et al. LEUKEMIA
- SB939, a Novel Potent and Orally Active Histone Deacetylase Inhibitor with High Tumor Exposure and Efficacy in Mouse Models of Colorectal Cancer
- (2010) V. Novotny-Diermayr et al. MOLECULAR CANCER THERAPEUTICS
- Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
- (2010) F. Baffert et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus Kinase 2: An Epigenetic 'Writer' that Activates Leukemogenic Genes
- (2010) J. He et al. Journal of Molecular Cell Biology
- Role of leukemia cell invadosome in extramedullary infiltration
- (2009) M. Stefanidakis et al. BLOOD
- Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
- (2009) J. Zhou et al. BLOOD
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
- (2009) Mark A. Dawson et al. NATURE
- Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
- (2008) L. Li et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now